← FDA DRUG APPROVALS

FDA NDA · NDA022500

CLONIDINE

Sponsor: ROSEMONT

APPLICATION
NDA022500
TYPE
NDA
ORIGINAL APPROVAL
2009-12-03
LATEST ACTION
2010-09-23
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription, Discontinued

Products

NEXICLON XRPrescription
CLONIDINE EQ 0.17MG BASE · TABLET, EXTENDED RELEASE · ORAL
NEXICLON XRDiscontinued
CLONIDINE EQ 0.26MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2010-09-23Labeling · Supplement 1 · unknown — Letter ↗AP
2009-12-03Type 3 - New Dosage Form · Original · standard — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →